Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants

Core Viewpoint - Verastem Oncology has announced the pricing of its public offering, indicating a strategic move to raise capital for advancing its biopharmaceutical initiatives focused on RAS/MAPK pathway-driven cancers [1] Company Summary - The company is offering 8,543,794 shares of common stock at a price of $7.25 per share [1] - Additionally, the offering includes pre-funded warrants for certain investors, allowing the purchase of up to 3,870,000 shares of common stock [1]